Selecta Biosciences Inc at Jefferies Gene Therapy/Editing Summit (Virtual) Transcript
Hi, everyone. My name is Maury Raycroft and I'm one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to welcome Carsten Brunn, the CEO of Selecta Biosciences. Thanks for joining us today, Carsten.
Thanks for having me, Maury. I'll be making forward-looking statements so please take notice. So just want to start giving a bit of an overview. So Selecta is an immune tolerance platform company. Our technology is called ImmTOR, which is a biodegradable nanoparticle that encapsulates the immunomodulator rapamycin, and what it does is it induces antigen-specific immune tolerance. We have several applications. I really want to focus on gene therapy in this talk, but I want to touch at least on the others as we have pretty significant clinical data and advanced assets in Phase 3.
So there's three pillars to the pipeline. The first, we use ImmTOR to redose highly immunogenic enzymes. The indication here is chronic
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |